Πέμπτη 11 Οκτωβρίου 2018

The clinical value of assays detecting antibodies against domain I of β2-glycoprotein I in the antiphospholipid syndrome

Publication date: Available online 11 October 2018Source: Autoimmunity ReviewsAuthor(s): Dongmei Yin, Bas de Laat, Katrien M.J. Devreese, Hilde KelchtermansAbstractAs the clinical symptoms of the antiphospholipid syndrome (APS) frequently occur irrespective of the syndrome, diagnosis predominantly depends on the laboratory assays measuring the level or function of antiphospholipid antibodies (aPLs). β2-glycoprotein I (β2GPI) is increasingly accepted as the most important target of aPLs. Anti-β2GPI antibodies constitute a heterogeneous population, but current in vivo and in vitro evidence show that especially the first domain (DI) of β2GPI contains an important pathogenic epitope. This epitope containing Glycine40-Arginine43 (G40-R43) has proven to be cryptic and only exposed when β2GP...

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2yxEfih

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.